| P2093 | author name string | P Kurtzhals | |
| P2860 | cites work | Crystal structure of a prolonged-acting insulin with albumin-binding properties | Q27734944 |
| | Insulin analogs with improved pharmacokinetic profiles | Q33933381 |
| | Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell | Q34275166 |
| | Physiological insulin replacement in type 1 diabetes mellitus | Q34312094 |
| | The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. | Q34315974 |
| | Insulins today and beyond | Q34365284 |
| | New insulins in the treatment of diabetes mellitus | Q34701220 |
| | Absorption of isophane (NPH) insulin and its clinical implications. | Q34762491 |
| | Variability of insulin absorption and insulin action | Q35008637 |
| | Limitations to subcutaneous insulin administration in type 1 diabetes | Q35149357 |
| | Insulin analogues and other developments in insulin therapy for diabetes | Q35164710 |
| | Monomeric insulins and their experimental and clinical implications | Q37977223 |
| | Novel forms of insulin delivery | Q40881594 |
| | Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin | Q41696877 |
| | Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo | Q41861199 |
| | Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency | Q42177647 |
| | Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion | Q43901566 |
| | Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake | Q43901624 |
| | A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes | Q44526983 |
| | Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes | Q44909481 |
| | Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. | Q55033955 |
| | The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin | Q57599459 |
| | Monomeric insulins obtained by protein engineering and their medical implications | Q59060531 |
| | The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges | Q59311929 |
| | Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties: Evidence From Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans | Q67868378 |
| | Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus | Q68134802 |
| | Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain | Q68245775 |
| | Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30 | Q68245778 |
| | Basal and 24-h C-peptide and insulin secretion rate in normal man | Q68950608 |
| | Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients | Q69923821 |
| | The cobalt(III)-insulin hexamer is a prolonged-acting insulin prodrug | Q71520692 |
| | Action Profile of Cobalt(III)-Insulin: A Novel Principle of Protraction of Potential Use for Basal Insulin Delivery | Q71816863 |
| | Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens | Q73179764 |
| | Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans | Q73824586 |
| | Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo | Q73840622 |
| | Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use | Q73922459 |
| | Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue | Q74017384 |
| | Insulin detemir: improving the predictability of glycaemic control | Q80442184 |
| P921 | main subject | pharmacology | Q128406 |
| | insulin detemir | Q410965 |
| P304 | page(s) | S23-8 | |
| P577 | publication date | 2004-09-01 | |
| P1476 | title | Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir | |
| P478 | volume | 28 Suppl 2 | |